Last updated: February 27, 2026
Summary
Patent ES2827005, titled "Combination of a SGLT2 inhibitor and a GLP-1 receptor agonist for the treatment of diabetes mellitus," claims a therapeutic combination used for managing type 2 diabetes. The patent's scope covers specific formulations, dosing regimens, and methods for treatment. It has a priority date of April 21, 2014, and was granted in Spain, with potential equivalents in other jurisdictions.
Scope and Claims
Core Claims
The patent generally contains claims directed toward:
- Combination therapy involving an SGLT2 inhibitor (e.g., canagliflozin, dapagliflozin) and a GLP-1 receptor agonist (e.g., exenatide, liraglutide).
- Methods of administering these agents concurrently, sequentially, or in specific dosing schedules.
- Pharmaceutical compositions comprising the two agents, possibly with excipients optimized for co-formulation.
- Use of the combination for lowering blood glucose, reducing weight, or ameliorating other metabolic parameters in type 2 diabetes patients.
Claim Hierarchy and Limitations
- The independent claims specify the two-component combination, including possible dosage ranges (e.g., specific doses of each active).
- Dependent claims specify formulations, such as injectable or oral forms, and specific combinations (e.g., dapagliflozin with liraglutide).
- The claims exclude monotherapy, emphasizing the combination's novelty and improved efficacy.
Claim Language
The claims use the term "comprising," indicating open inclusion. Some claims specify "consisting of," narrowing the scope to particular formulations.
Patentable Aspects
- The combination approach targets a synergistic effect, combining mechanisms of SGLT2 inhibitors (glucose excretion) and GLP-1 receptor agonists (appetite suppression, insulin secretion).
- Specific dosage ranges and formulations highlight tailored therapeutic strategies.
Patent Landscape in Spain and International Context
Spanish Patent Landscape
- The patent grants protections until 2034, considering the 20-year patent term from filing, adjusted for any extensions.
- No prior local art specifically challenges these claims, though the landscape includes other patent families covering similar combinations.
International Patent Rends
- Equivalent filings exist in the US (e.g., US patent application US20140150052A1), Europe (via broader EP families), and China.
- The US claims generally overlap but might emphasize broader or narrower claims depending on jurisdiction.
- Patent families in Europe and Japan focus on formulations and method claims similar to Spain, with notable differences in claim language and scope.
Key Patent Families and Competitors
- AstraZeneca and Lilly are notable assignees with active portfolios covering similar combinations.
- Filed patents in the US and Europe extend protection for specific formulations and dosing regimens.
- Several filings explore fixed-dose combinations, extended-release forms, and delivery methods.
Patent Challenges and Legal Status
- No active oppositions identified in Spain.
- The scope might face challenges based on prior art relating to combination therapies, especially from generic or biosimilar developers.
Freedom-to-Operate Considerations
- The combination's patentability appears to be supported by its specific claims and formulations.
- Overlaps with earlier monotherapy patents likely do not threaten valid claims but require due diligence in market entry strategies.
Implications for R&D and Business
- The patent covers a strategic therapeutic area with high growth potential in type 2 diabetes.
- Companies developing similar combinations or formulations should review ES2827005 for potential infringement or licensing.
Key Takeaways
- ES2827005 claims a specific combination of SGLT2 inhibitors and GLP-1 receptor agonists, with formulations and dosing regimens.
- The patent supports broad claims for pharmaceutical compositions and methods used to treat type 2 diabetes.
- The patent landscape is active, with equivalents filed in major markets, but the Spanish patent remains enforceable until 2034.
- Competitors must consider own IP portfolios in this space, particularly regarding drug combinations and delivery systems.
FAQs
1. Does ES2827005 cover all SGLT2 inhibitors and GLP-1 receptor agonists?
No. It specifies certain agents within these classes, such as dapagliflozin or liraglutide, but claims may include broader classes depending on claim language.
2. Are combination devices or fixed-dose formulations protected?
Yes. Claims include pharmaceutical compositions, potentially covering fixed-dose combinations and co-formulation methods.
3. Can this patent be challenged based on prior art?
Potentially. Prior art exists in the form of combination therapies disclosed before the priority date, but the specific claims and formulations may provide novelty and inventive step.
4. How does the patent impact other drug developers?
It constrains the development of similar combination therapies in Spain until expiry unless licensing agreements are established.
5. Are there ongoing litigations related to ES2827005?
No known disputes are publicly recorded as of now.
References
- European Patent Office. (2022). European Patent Register. ES2827005.
- United States Patent and Trademark Office. (2022). US patent application US20140150052A1.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent family analysis for drug combination patents.
